Search Within

Chrisann Kyi Kyi

  1. "Maria Zlobinsky"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (8)
  2. GDMT, Medicine (8)
  3. Gynecologic Medicine Service (8)
  4. Gynecology Disease Management Team (8)
  5. Solid Tumor Oncology Division (8)
  6. Weinberg Fellows (8)

More Groups

People
  1. Carol Aghajanian (8)
  2. Claire Friedman (8)
  3. Maria Zlobinsky (8)
  4. Vicky Makker (8)
  5. Rachel Grisham (7)
  6. Roisin O'Cearbhaill (7)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (1)
  5. 2021 (1)
  6. 2019 (1)
Publications
  1. Gynecologic Oncology (4)
  2. Journal of Clinical Oncology (2)
  3. International Journal of Gynecological Cancer (1)
  4. Nature Medicine (1)
Publishers
  1. Elsevier Inc. (4)
  2. American Society of Clinical Oncology (2)
  3. Lippincott Williams & Wilkins (1)
  4. Nature Publishing Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate
    Journal Article

    Johannet, P.; Flint, M.; Chui, M. H.; Konner, J.; Friedman, C.; Green, A. K.; Guo, R.; Hensley, M. L.; Kyi, C.; Liu, Y.; more...
    Gynecologic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy and safety profile of mirvetuximab in folate receptor alpha-positive ovarian cancer
    Meeting Abstract

    Johannet, P.; Foote, M.; Cohen, S.; Friedman, C.; Green, A.; Guo, R.; Hensley, M.; Konner, J.; Kyi, C.; Liu, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers
    Journal Article

    Rubinstein, M. M.; Grisham, R. N.; Cadoo, K.; Kyi, C.; Tew, W. P.; Friedman, C. F.; O'Cearbhaill, R. E.; Zamarin, D.; Zhou, Q.; Iasonos, A.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save